The economic and humanistic burden of graft-versus-host disease (GVHD) in pediatric patients.
Average Additional All-Cause Cost: ~US$500k
I assume Mesoblast would expect ~$300k reimbursement once you factor in the cost to the US is US$500K per patient.
1,000 patients would generate US$300m in sales just out of the US for SR-aGVHD in children.
MSB Trading - 2020, page-839
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |